Document Type : Original Article (s)
Authors
1
MSc Student, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2
Professor, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3
MSc Student, Department of Microbiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
4
Associate Professor, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5
PhD Candidate, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
6
Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Herpes simplex virus type 1 (HSV-1) infections are of the most common diseases in human population. HSV-1 can cause subclinical to severe diseases, especially in immunocompromised patients. There are few anti-herpes drugs for treatment of HSV-1 infection. Acyclovir is one of the most important drugs. The extensive use of this drug has led to the development of resistant strains. Therefore, development of new anti- herpes drugs with different mechanisms is noticeable. This study aimed to use microRNAs as a novel method for inhibiting HSV-1 infection.Methods: Synthesized miRNA mimics hsa-miR-7704 (miR-SX1) were transfected into Hela cells, and then infected with HSV-1. Cellular morphological changes were observed 24 hours post-infection by inverted microscope, and photographed. Viral titers were measured using 50% tissue culture infective dose (TCID50) method.Findings: miR-SX-1-transfected cells produced low-titer HSV-1, without affecting cell viability.Conclusion: The data suggest that miR-SX1 inhibits HSV-1 replication, and may provide an alternative mechanism to prevent HSV-1 infection.
Keywords